GUARDIAN-101: A first in human, tumor agnostic phase 1 study evaluating safety and preliminary antitumor activity of CLSP-1025. Oct 18 Written By Rachel Swansburg GO BACK TO PRESS RELEASES & MEDIA PresentationOctober 19, 2025 GUARDIAN-101: A first in human, tumor agnostic phase 1 study evaluating safety and preliminary antitumor activity of CLSP-1025, a first in class, HLA-directed T cell engager (TCE) for advanced solid tumors harboring the p53 R175H mutation. Presentation Rachel Swansburg
GUARDIAN-101: A first in human, tumor agnostic phase 1 study evaluating safety and preliminary antitumor activity of CLSP-1025. Oct 18 Written By Rachel Swansburg GO BACK TO PRESS RELEASES & MEDIA PresentationOctober 19, 2025 GUARDIAN-101: A first in human, tumor agnostic phase 1 study evaluating safety and preliminary antitumor activity of CLSP-1025, a first in class, HLA-directed T cell engager (TCE) for advanced solid tumors harboring the p53 R175H mutation. Presentation Rachel Swansburg
